Search

Objective Mitochondrial pyruvate dehydrogenase kinases 1–4 (PDKs1–4) negatively regulate activity of the pyruvate dehydrogenase complex (PDC) by reversible phosphorylation. PDKs play a pivotal role in maintaining energy homeostasis and contribute to metabolic flexibility by attenuating PDC activity in various mammalian tissues. Cumulative evidence has shown that the up-regulation of PDK4 expression is tightly associated with obesity and diabetes. In this investigation, we test the central hypothesis that PDKs1-4 are a pharmacological target for lowering glucose levels and restoring insulin sensitivity in obesity and type 2 diabetes (T2D). Methods Diet-induced obese (DIO) mice were treated with a liver-specific pan-PDK inhibitor 2-[(2,4-dihydroxyphenyl) sulfonyl]isoindoline-4,6-diol (PS10) for four weeks, and results compared with PDK2/PDK4 double knockout (DKO) mice on the same high fat diet (HFD). Results Both PS10-treated DIO mice and HFD-fed DKO mice showed significantly improved glucose, insulin and pyruvate tolerance, compared to DIO controls, with lower plasma insulin levels and increased insulin signaling in liver. In response to lower glucose levels, phosphorylated AMPK in PS10-treated DIO and HFD-fed DKO mice is upregulated, accompanied by decreased nuclear carbohydrate-responsive element binding protein (ChREBP). The reduced ChREBP signaling correlates with down-regulation of hepatic lipogenic enzymes (ACC1, FAS, and SCD1), leading to markedly diminished hepatic steatosis in both study groups, with lower circulating cholesterol and triacylglyceride levels as well as reduced fat mass. PS10-treated DIO as well as DKO mice showed predominant fatty acid over glucose oxidation. However, unlike systemic DKO mice, increased hepatic PDC activity alone in PS10-treated DIO mice does not raise the plasma total ketone body level. Conclusion Our findings establish that specific targeting of hepatic PDKs with the PDK inhibitor PS10 is an effective therapeutic approach to maintaining glucose and lipid homeostasis in obesity and T2D, without the harmful ketoacidosis associated with systemic inhibition of PDKs. [ABSTRACT FROM AUTHOR]

Abstract: In this study, the biodegradable poly(lactic acid) (PLA)/montmorillonite (MMT) nanocomposites were successfully prepared by the solution mixing process of PLA polymer with organically-modified montmorillonite (m-MMT), which was first treated by n-hexadecyl trimethyl-ammonium bromide (CTAB) cations and then modified by biocompatible/biodegradable chitosan to improve the chemical similarity between the PLA and m-MMT. Both X-ray diffraction data and transmission electron microscopy images of PLA/m-MMT nanocomposites indicate that most of the swellable silicate layers were disorderedly intercalated into the PLA matrix. Mechanical properties and thermal stability of the PLA/m-MMT nanocomposites performed by dynamic mechanical analysis and thermogravimetric analysis have significant improvements in the storage modulus and 50% loss in temperature when compared to that of neat PLA matrix. The degradation rates of PLA/m-MMT nanocomposites are also discussed in this study. [Copyright &y& Elsevier]